europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

EuropaBio response to the European Commission Public Consultation on the Regulations for Orphan Medicinal Products and Paediatrics

02/08/2021
PRESS RELEASE
EuropaBio response to the European Commission Public Consultation on the Regulations for Orphan Medicinal Products and Paediatrics

Brussels, 2 August 2021 - EuropaBio has responded to the European Commission’s public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.

EuropaBio made it clear that the EU incentives framework has successfully driven the development of medicines for rare and paediatric conditions, with the number of medicines in development significantly increasing since the introduction of the legislation (with 3,678 applications for orphan designation submitted by the end of 2020.)

It is estimated that 80% of rare disease patients suffer from just 4% of the known rare conditions. While most orphan drugs developed so far address conditions affecting these 80% of patients, this still leaves a significant number of patients lacking sufficient treatment options, particularly those with conditions which can be considered “ultra-rare.”

EuropaBio acknowledges the need to further encourage R&D in these under-served conditions and is ready to engage all stakeholders to search for potential solutions. To begin this discussion, in its response to the consultation, EuropaBio has suggested several options worth exploring e.g., a new model for public-private partnerships, building upon the European Reference networks, and utilising the upcoming European Health Data Space for rare disease research.

EuropaBio emphasises the immensely positive impact the incentives framework has had on encouraging the development of new therapies for rare and paediatric patient groups. We therefore call upon the European Commission to approach any proposed revision of the legislation with utmost caution, carefully avoiding any potentially negative impact on the environment for rare & paediatric R&D in the EU. Any revision of the legislation should learn from, and build upon, its prior successes, while paying careful attention not to undo them.

EuropaBio remains fully committed to being a constructive partner in the ongoing and upcoming discussions, in the interest of encouraging the development and delivery of new therapies for patients.

To view our full response to the public consultation, please click here.

EuropaBio response to the European Commission Public Consultation on the Regulations for Orphan Medicinal Products and Paediatrics


Download

Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
16/03/2023

Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies